Metabolon公司公布了一項(xiàng)來自美國腦健康研究院(NIH, Bethesda, MD, USA)的鑒別婦女經(jīng)前期煩躁疾病(PMDD)的合同。

PMDD是一種嚴(yán)重的經(jīng)前期綜合征，影響大約5％的行經(jīng)婦女。癥狀包括抑郁、煩躁、緊張、易激惹和喜怒無常?；加蠵MDD女性的生活質(zhì)量出現(xiàn)顯著下降。盡管該疾病是由生殖激素所觸發(fā)的，但是PMDD的病因目前尚不清楚。目前的治療方案包括使用營養(yǎng)藥物添加劑和某些處方藥物治療。

Metablon科學(xué)家將對(duì)采集自患PMDD婦女和正常健康婦女的樣本進(jìn)行對(duì)比研究。然后分析所獲得的資料試圖鑒別出反應(yīng)這兩組人群的代謝差異的生物指標(biāo)。這項(xiàng)研究的成果或許能夠產(chǎn)生對(duì)這項(xiàng)疾病更有效的治療方法。

Metabolon公司商業(yè)開發(fā)副總裁Reid Tripp說：“Metabolon的技術(shù)能夠鑒別出幫助開發(fā)治療這種疾病本身的生物學(xué)指標(biāo)，而不僅僅是針對(duì)癥狀。這項(xiàng)研究能夠加強(qiáng)對(duì)代謝性疾病多樣性和深度的研究。Metabolon一直受到政府、學(xué)院和工業(yè)單位的委托，研究對(duì)多種未來能夠治療疾病的方法?！?
 
Biomarkers for Premenstrual Disorder
 
A contract from the U.S. National Institute of Mental Health (NIH, Bethesda, MD, USA) to identify biomarkers occurring in women with premenstrual dysphoric disorder (PMDD) has been announced by Metabolon, Inc. (Research Triangle Park, NC, USA).

PMDD is a severe form of premenstrual syndrome that affects about 5% of menstruating women. Symptoms include depression, anxiety, tension, irritability, and moodiness. Women with PMDD often have a significantly reduced quality of life. Although the disorder is triggered by reproductive hormones, the cause of PMDD is not known. Current treatment options include nutritional supplements and prescription drugs.

Metablon scientists will compare samples taken from women with PMDD with samples from normal healthy women. They will then analyze the data to identify biomarkers that indicate a metabolic difference between the two groups. Results from this study may lead to more effective treatments for the disorder.

“Metabolon’s technology will identify biomarkers that can be used to develop new treatments for the disorder itself, not just the symptoms,” said Reid Tripp, vice president, business development, at Metabolon. “This study reinforces the diversity and depth of metabolomics applications. Metabolon continues to be sought out by government, academia, and industry to find biomarkers that may impact the way various disorders are treated in the future.”